{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464378463
| IUPAC_name = (3''S'')-2-[(2''S'')-2-<nowiki>[[</nowiki>(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1''H''-isoquinoline-3-carboxylic acid
| image = Quinapril structure.svg
| width = 222

<!--Clinical data-->
| tradename = Accupril
| Drugs.com = {{drugs.com|monograph|quinapril-hydrochloride}}
| MedlinePlus = a692026
| pregnancy_category = D
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 97%
| metabolism =  
| elimination_half-life = 2 hours

<!--Identifiers-->
| IUPHAR_ligand = 6350
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 85441-61-8
| ATC_prefix = C09
| ATC_suffix = AA06
| PubChem = 54892
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00881
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 49565
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RJ84Y44811
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03752
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8713
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1592

<!--Chemical data-->
| C=25 | H=30 | N=2 | O=5
| molecular_weight = 438.516 g/mol
| smiles = O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)Cc1c(cccc1)C2)C)CCc3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JSDRRTOADPPCHY-HSQYWUDLSA-N
| melting_point     = 120
| melting_high      = 130
}}

'''Quinapril''' (marketed under the brand name Accupril by [[Pfizer]]) is an [[angiotensin-converting enzyme]] [[enzyme inhibitor|inhibitor]] ([[ACE inhibitor]]) used in the treatment of [[hypertension]] and [[congestive heart failure]]. A [[prodrug]], it is converted to its active [[metabolite]], [[quinaprilat]], in the liver.

==Mechanism of action==
{{main|ACE inhibitor}}
{{see also|Angiotensin|renin-angiotensin system}}

Quinapril inhibits [[angiotensin converting enzyme]], an enzyme which [[catalysis|catalyses]] the formation of [[angiotensin]] [[Angiotensin#Angiotensin II|II]] from its precursor, [[Angiotensin#Angiotensin I|angiotensin I]]. Angiotensin II is a powerful [[vasoconstrictor]] and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin production, plasma concentrations of [[aldosterone]] are also reduced, resulting in increased excretion of [[sodium]] in the urine and increased concentrations of [[potassium]] in the blood.

==Indications==
Quinapril is indicated for the treatment of high blood pressure ([[hypertension]]) and as adjunctive therapy in the management of [[heart failure]]. It may be used for the treatment of hypertension by itself or in combination with [[thiazide diuretic]]s, and with diuretics and [[digoxin]] for heart failure.

==Contraindications==
* Pregnancy
* Impaired renal and liver function
* Patients with a history of angioedema related to previous treatment with an ACE inhibitor
* Hypersensitivity to quinapril

==Side effects==
[[Adverse drug reaction|Side effect]]s of quinapril include dizziness, cough, vomiting, upset stomach, [[angioedema]], and [[fatigue (medical)|fatigue]].

==External links==
* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a692026.html Quinapril FAQ]
* [https://web.archive.org/web/20080705012834/http://www.accupril.com/ Accupril Site]

{{ACE inhibitors}}
{{Angiotensin receptor modulators}}

[[Category:ACE inhibitors]]
[[Category:Carboxamides]]
[[Category:Butyrates]]
[[Category:Enantiopure drugs]]
[[Category:Pfizer products]]
[[Category:Pfizer]]
[[Category:Prodrugs]]
[[Category:Tetrahydroisoquinolines]]